178 related articles for article (PubMed ID: 25081642)
1. The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease.
Tavassoly O; Kakish J; Nokhrin S; Dmitriev O; Lee JS
Eur J Med Chem; 2014 Dec; 88():42-54. PubMed ID: 25081642
[TBL] [Abstract][Full Text] [Related]
2. Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
Tavassoly O; Lee JS
FEBS Lett; 2012 Sep; 586(19):3222-8. PubMed ID: 22771474
[TBL] [Abstract][Full Text] [Related]
3. Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?
Kakish J; Lee D; Lee JS
ACS Chem Neurosci; 2015 Dec; 6(12):1930-40. PubMed ID: 26378986
[TBL] [Abstract][Full Text] [Related]
4. Novel Dimer Compounds That Bind α-Synuclein Can Rescue Cell Growth in a Yeast Model Overexpressing α-Synuclein. A Possible Prevention Strategy for Parkinson's Disease.
Kakish J; Allen KJ; Harkness TA; Krol ES; Lee JS
ACS Chem Neurosci; 2016 Dec; 7(12):1671-1680. PubMed ID: 27673434
[TBL] [Abstract][Full Text] [Related]
5. Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field.
Jakova E; Lee JS
Electrophoresis; 2017 Jan; 38(2):350-360. PubMed ID: 27570136
[TBL] [Abstract][Full Text] [Related]
6. Cu(II) and dopamine bind to α-synuclein and cause large conformational changes.
Tavassoly O; Nokhrin S; Dmitriev OY; Lee JS
FEBS J; 2014 Jun; 281(12):2738-53. PubMed ID: 24725464
[TBL] [Abstract][Full Text] [Related]
7. Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein.
Kakish J; Tavassoly O; Lee JS
ACS Chem Neurosci; 2015 Feb; 6(2):347-55. PubMed ID: 25514361
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
9. Analysis of a single α-synuclein fibrillation by the interaction with a protein nanopore.
Wang HY; Gu Z; Cao C; Wang J; Long YT
Anal Chem; 2013 Sep; 85(17):8254-61. PubMed ID: 23899046
[TBL] [Abstract][Full Text] [Related]
10. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
11. Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease.
Kardani J; Sethi R; Roy I
Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1454-1463. PubMed ID: 28167231
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
13. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
14. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
15. Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.
Kardani J; Roy I
ACS Chem Neurosci; 2015 Sep; 6(9):1613-25. PubMed ID: 26167732
[TBL] [Abstract][Full Text] [Related]
16. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
Tóth G; Gardai SJ; Zago W; Bertoncini CW; Cremades N; Roy SL; Tambe MA; Rochet JC; Galvagnion C; Skibinski G; Finkbeiner S; Bova M; Regnstrom K; Chiou SS; Johnston J; Callaway K; Anderson JP; Jobling MF; Buell AK; Yednock TA; Knowles TP; Vendruscolo M; Christodoulou J; Dobson CM; Schenk D; McConlogue L
PLoS One; 2014; 9(2):e87133. PubMed ID: 24551051
[TBL] [Abstract][Full Text] [Related]
17. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease.
Bharathi ; Rao KS
Biochem Biophys Res Commun; 2007 Jul; 359(1):115-20. PubMed ID: 17531952
[TBL] [Abstract][Full Text] [Related]
20. Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding.
Yamaguchi Y; Masuda M; Sasakawa H; Nonaka T; Hanashima S; Hisanaga S; Kato K; Hasegawa M
J Mol Biol; 2010 Jan; 395(3):445-56. PubMed ID: 19895818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
